Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. (Q54176069)

25 May 2018

title

Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. (English)

1 reference

25 May 2018

1 reference

1 reference

1 reference

Bente Klarlund Pedersen

4

1 reference

25 May 2018

B Baslund

3

object named as

B Baslund

1 reference

25 May 2018

author name string

A Rosenvinge

1

1 reference

25 May 2018

R Krogh-Madsen

2

1 reference

25 May 2018

publication date

1 March 2007

1 reference

25 May 2018

Scandinavian Journal of Rheumatology

published in

1 reference

25 May 2018

volume

36

1 reference

25 May 2018

issue

2

1 reference

25 May 2018

page(s)

91-96

1 reference

25 May 2018

Comorbidity in rheumatoid arthritis.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Risk factors for the development of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

A tale of two diseases: atherosclerosis and rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Inflammation: the link between insulin resistance, obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

The anti-inflammatory effect of exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

The expression of TNF alpha by human muscle. Relationship to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Role of cytokines in inducing hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Evidence for peripheral impaired glucose handling in patients with connective tissue diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Use and abuse of HOMA modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Effects of exercise and diet on chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

New therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Interleukin-6 induces cellular insulin resistance in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Interleukin-6 depletion selectively improves hepatic insulin action in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Interleukin-6-deficient mice develop mature-onset obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long‐term infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

Atlizumab: anti-IL-6 receptor antibody-Chugai, anti-interleukin-6 receptor antibody-Chugai, MRA-Chugai

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740601179605

10.1080/03009740601179605

21 January 2018

Identifiers

DOI

1 reference

25 May 2018

PubMed ID

17476613

1 reference

25 May 2018